absk-011
Small moleculeexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 26, 2020 (NCT04906434)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor receptor 4INHIBITOR
FGFR4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N[C@H]1CCOC[C@H]1Nc1ncc2cc(-c3c(F)c(OC)cc(OC)c3F)nc(N3CC(C)(OC)C3)c2n1- Mol. weight
- 570.6 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314522 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07010497 | Phase 2 | Nov 14, 2025 | Abbisko Therapeutics Co, Ltd, University of Ulsan |
| NCT06978933 | Phase 2 | Apr 30, 2025 | Jiao Tong University |
| NCT06896760 | Phase 1 | Apr 7, 2025 | Abbisko Therapeutics Co, Ltd, Government of China |
| NCT06306872 | Phase 1 | Feb 23, 2024 | Abbisko Therapeutics Co, Ltd |
| NCT05441475 | Phase 2 | Dec 30, 2021 | Abbisko Therapeutics Co, Ltd |
| NCT04906434 | Phase 1 | Feb 26, 2020 | Abbisko Therapeutics Co, Ltd, National Taiwan University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbisko Therapeutics Co, Ltd | For profit | 5 | 4 | 2 | 2020 |
| Government of China | Government | 1 | 0 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| National Taiwan University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Ulsan | Academic/Hospital | 1 | 1 | 1 | 2025 |
5 organizations
Page 1 / 1